Fusion Antibodies Statistics

Total Valuation

Fusion Antibodies has a market cap or net worth of GBP 8.78 million. The enterprise value is 8.37 million.

Market Cap	8.78M
Enterprise Value	8.37M

Important Dates

The next estimated earnings date is Tuesday, February 18, 2025.

Earnings Date	Feb 18, 2025
Ex-Dividend Date	n/a

Share Statistics

Fusion Antibodies has 95.95 million shares outstanding. The number of shares has increased by 120.63% in one year.

Current Share Class	n/a
Shares Outstanding	95.95M
Shares Change (YoY)	+120.63%
Shares Change (QoQ)	+47.59%
Owned by Insiders (%)	4.05%
Owned by Institutions (%)	60.80%
Float	88.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.06
PB Ratio	8.24
P/TBV Ratio	8.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.26
EV / Sales	4.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.14

Financial Position

The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.03.

Current Ratio	3.25
Quick Ratio	2.73
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	-415.50

Financial Efficiency

Return on equity (ROE) is -129.49% and return on invested capital (ROIC) is -80.15%.

Return on Equity (ROE)	-129.49%
Return on Assets (ROA)	-57.93%
Return on Capital (ROIC)	-80.15%
Revenue Per Employee	66,741
Profits Per Employee	-58,926
Employee Count	27
Asset Turnover	1.01
Inventory Turnover	3.81

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.06% in the last 52 weeks. The beta is 0.33, so Fusion Antibodies's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+18.06%
50-Day Moving Average	6.38
200-Day Moving Average	4.26
Relative Strength Index (RSI)	60.96
Average Volume (20 Days)	1,740,387

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Fusion Antibodies had revenue of GBP 1.80 million and -1.59 million in losses. Loss per share was -0.02.

Revenue	1.80M
Gross Profit	364,000
Operating Income	-1.66M
Pretax Income	-1.66M
Net Income	-1.59M
EBITDA	-1.51M
EBIT	-1.66M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 439,000 in cash and 32,000 in debt, giving a net cash position of 407,000 or 0.00 per share.

Cash & Cash Equivalents	439,000
Total Debt	32,000
Net Cash	407,000
Net Cash Per Share	0.00
Equity (Book Value)	1.06M
Book Value Per Share	0.01
Working Capital	991,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.17 million and capital expenditures -2,000, giving a free cash flow of -1.17 million.

Operating Cash Flow	-1.17M
Capital Expenditures	-2,000
Free Cash Flow	-1.17M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 20.20%, with operating and profit margins of -92.23% and -90.29%.

Gross Margin	20.20%
Operating Margin	-92.23%
Pretax Margin	-92.18%
Profit Margin	-90.29%
EBITDA Margin	-83.85%
EBIT Margin	-92.23%
FCF Margin	n/a

Dividends & Yields

Fusion Antibodies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-120.63%
Shareholder Yield	-120.63%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Fusion Antibodies has an Altman Z-Score of -7.29. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.29
Piotroski F-Score	n/a